RecruitingNot ApplicableNCT06438445
Effects of Royal Jelly Supplementation in Chronic Kidney Disease
Effects of Royal Jelly Supplementation on Inflammation and Cellular Senescence in Chronic Kidney Disease Patients Under Hemodialysis
Sponsor
Universidade Federal Fluminense
Enrollment
30 participants
Start Date
Jul 30, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The objective of this study is to evaluate the effects of royal jelly on inflammation and cellular senescence in patients with chronic kidney disease (CKD) on hemodialysis (HD).
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Inclusion Criteria2
- patients with CKD undergoing hemodialysis for more than 6 months
- patients with arteriovenous fistula (AVF) as vascular access.
Exclusion Criteria6
- pregnant,
- lactating,
- smoker
- patients using antibiotics and antioxidant supplements in the last three months
- patients with autoimmune and infectious diseases,
- patients with cancer, liver disease, and AIDS
Interventions
DIETARY_SUPPLEMENTReal Jelly
Participants will receive 500mg of royal jelly capsules per day for two months.
DIETARY_SUPPLEMENTPlacebo
Participants will receive 500mg of placebo capsules per day for two months.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06438445
Related Trials
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
NCT074263802 locations
Expanded Hemodialysis Versus High-Volume Online Hemodiafiltration for Uremic Toxin Removal
NCT073485361 location
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
NCT0467177121 locations
Studies on Adsorption International Learning Initiative Global
NCT071239091 location
Effect of Modifying Magnesium Concentration in Citrate-enriched Dialysate on Hemodialysis-associated Thromboinflammation
NCT072065241 location